Yüklüyor......

DRES-03. PARP INHIBITOR, INHIBITION OF HOMOLOGOUS RECOMBINATION, OR DIANHYDRODULCITOL CAN OVERCOME TEMOZOLOMIDE-RESISTANCE IN GLIOMA CELLS

Glioblastoma is one of the most aggressive tumors in the central nervous system tumors, with 5-year survival rates of less than 10%. The standard therapy for glioblastomas is maximal safe resection, followed by radiation therapy and chemotherapy with temozolomide (TMZ). The acquisition of resistance...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Ohba, Shigeo, Hirose, Yuichi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2019
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847605/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.291
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!